UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015216
Receipt number R000016418
Scientific Title Effect of treatment with compression gloves and compression stockings to prevent paclitaxel-induced peripheral. neuropathy
Date of disclosure of the study information 2014/09/21
Last modified on 2016/09/05 11:10:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of treatment with compression gloves and compression stockings to prevent paclitaxel-induced peripheral. neuropathy

Acronym

gloves and stockings to prevent paclitaxel-induced peripheral neuropathy

Scientific Title

Effect of treatment with compression gloves and compression stockings to prevent paclitaxel-induced peripheral. neuropathy

Scientific Title:Acronym

gloves and stockings to prevent paclitaxel-induced peripheral neuropathy

Region

Japan


Condition

Condition

non small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

By wearing compression gloves and compression stockings at start of chemotherapy, we analyze period to occurrence, frequency, and extent of peripheral neuropathy. We also evaluate relationship among peripheral neuropathy and effect and dose intensity of chemotherapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The incidence of peripheral neuropathy in the third cycle before starting

Key secondary outcomes

1) period to development of neurotoxicity (grade 2 or more)
2)proportion of cases who experience contra-lateral neuropathy previous to intervention side.
3) grade of neuropathy
4)relationship among proportion of neuropathy and proportion of completion and effect of chemotherapy.
5) safety of compression gloves and compression stockings.


Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

May26,2014-May31,2015

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) planning to treat with paclitaxel and nob-paclitaxel.
2) 20 years old or more
3) no neuropahty before enrollment
4) controlled diabetes mellitus (DM) or no DM
5) no significant skin disorder of extremities

Key exclusion criteria

1) any grade of neurotoxicity
2) no ability to express toxicity
3) significant skin disorder of extremites
4) symptomatic brain metastasis

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Maemondo

Organization

Miyagi Cancer Center

Division name

respiratory medicine

Zip code


Address

47-1 Nodayama Shiote aza Medeshima Natorishi Miyagi

TEL

022-384-3151

Email

maemondo-ma693@niyagi-pho.jp


Public contact

Name of contact person

1st name
Middle name
Last name Makoto Maemondo

Organization

Miyagi Cancer Center

Division name

respiratory medicine

Zip code


Address

47-1 Nodayama Shiote aza Medeshima Natorishi Miyagi

TEL

022-384-3151

Homepage URL


Email

maemondo-ma693@niyagi-pho.jp


Sponsor or person

Institute

Miyagi Cancer center

Institute

Department

Personal name



Funding Source

Organization

Miyagi Cancer Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 21 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 05 Month 13 Day

Date of IRB


Anticipated trial start date

2014 Year 05 Month 27 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 09 Month 21 Day

Last modified on

2016 Year 09 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016418


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name